15 results about "Phosphodiesterase" patented technology

The invention relates in general to the field of CAR-T cells. The invention in particular relates to improved methods for obtaining CAR-T cells, and improved CAR-T cells, as well as uses thereof. The method in further relates to activating or expressing a phosphodiesterase (PDE) in T-cells during CAR-T cell generation.

This invention discloses a genetically engineered bacterium capable of synthesizing large quantities of natural cyclic diguanylate (c-di-GMP) and its applications. It involves knocking out the major phosphodiesterase gene chr1_233 as described in claim 1 within the sphingobium xenophagum C2 strain. This invention rationally designs and modifies the c-di-GMP synthesis and degradation pathways and the inhibitory site of major diguanylate cyclase activity in heterologous sphingobium-consuming bacteria, constructing a series of genetically engineered bacteria capable of synthesizing large quantities of natural c-di-GMP. This provides the industry with a green, simple, economical, and efficient method for producing natural c-di-GMP, and offers a series of high-quality and inexpensive raw materials for the preparation of STING agonists or immune adjuvants, or for the preparation of drugs for treating diseases related to STING protein function.

The present disclosure relates generally to processes for providing compounds that can be used as inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1), which inhibitors can be useful in treating or preventing soft bone diseases, such as hypophosphatasia (HPP).

This invention relates to pharmaceutical compositions, including compositions adapted for intranasal administration, comprising an active ingredient, including dexmedetomidine, pomalidomide, a selective phosphodiesterase type 4 inhibitor such as roflumilast, or combinations thereof, useful in the treatment of traumatic brain injury (TBI), including to prevent or reduce the neurological sequalae of TBI.

A method of reducing fear memory in a mammal comprising the step of inhibiting or reducing cAMP signaling in the mammal. The cAMP signaling can be reduced using an adenylyl cyclase 1 (AC1) inhibitor or using a phosphodiesterase, such as a cAMP-specific phosphodiesterase, such as PDE4.

The present invention provides combinations of inhibitors of Ectonucleotide Pyrophosphatase / Phosphodiesterase (ENPP1) with a radiation therapy or a radioligand for the purposes of treating cancer. The invention includes both methods of treatment of cancer with the provided combinations and pharmaceutical compositions comprising such combinations. A preferred ENPP1 inhibitor is SR-8541A; and a preferred radioligand is PluvictoTM.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating calcium pyrophosphate deposition disease and hypophosphatasia, comprising a benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase.

The application belongs to the technical field of biological medicine, and particularly relates to a substituted cyano quinolinone compound and a preparation method and application thereof. The substituted cyano quinolinone compound has a significant inhibitory effect on phosphodiesterase type I, has a significant therapeutic effect on animal models of phosphodiesterase related diseases, lung fibrosis, intestinal inflammation and the like, and can be developed into a new target candidate drug for inflammatory diseases such as lung fibrosis and intestinal inflammation. Moreover, the preparation method of the substituted cyano quinolinone compound is simple, the reaction condition is mild, and is very suitable for large-scale industrial production.

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors in combination with a Compound of Formula VIII or a Compound of Formula IX, as described herein, or in combination with an antiemetic agent, such as an antipsychotic agent, e.g., olanzapine, for preventing or treating nausea and / or vomiting, e.g., CINV (chemotherapy-induced nausea and vomiting). In some embodiments, the Compound of Formula VIII or the Compound of Formula IX is used as mono-therapy (i.e., without a PDE1 inhibitor).

This invention relates to the field of enzyme preparation and fragrance beads, and particularly to an enzyme preparation and its preparation method, as well as deodorizing and odor-removing fragrance beads. The enzyme preparation comprises a composite enzyme microcapsule and a protease microcapsule in a mass ratio of (3-6):1. By mass parts, the core material of the composite enzyme microcapsule comprises: 12-15 parts lipase, 2-4 parts amylase, 5-8 parts fig lysozyme, 2-4 parts cellulase, 1-3 parts pectinase, and 1-3 parts phosphodiesterase (PDE). When the enzyme preparation of this invention is added to fragrance beads, it can effectively improve the antibacterial, deodorizing, and odor-removing effects of the fragrance beads.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a purine PDE8 inhibitor and a preparation method and application thereof. The purine compound provided by the application has good inhibitory effect on phosphodiesterase type 8 and low inhibitory activity concentration, can be applied to the preparation of a medicine for treating and / or preventing diseases related to phosphodiesterase type 8, has good development potential, and increases the selectable range of medicines for treating diseases related to phosphodiesterase type 8.